Monoclonal antibodies
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified: > Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes: > Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale > Monoclonal antibodies
Duty Rate (from China)
Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Products classified under HTS 3002.13.00.10
Rituximab Monoclonal Antibody
Rituximab is a genetically engineered chimeric monoclonal antibody targeting CD20 on B-cells, used primarily for treating non-Hodgkin lymphoma and rheumatoid arthritis. It falls under HTS 3002.13.0010 as an unmixed immunological product consisting of monoclonal antibodies obtained via biotechnological processes, not put up in measured doses for retail sale. This classification applies to bulk pharmaceutical-grade preparations for further formulation.
Trastuzumab Monoclonal Antibody
Trastuzumab (Herceptin) is a humanized monoclonal antibody that inhibits HER2 protein, used in HER2-positive breast cancer therapy. Classified under HTS 3002.13.0010 as an unmixed monoclonal antibody product from biotechnological processes, supplied in bulk for pharmaceutical compounding. It regulates immunological processes via antibody targeting as defined in Chapter 30 notes.
Cetuximab Monoclonal Antibody
Cetuximab (Erbitux) targets EGFR for colorectal and head/neck cancer therapy, a chimeric monoclonal antibody. Bulk unmixed form imports under HTS 3002.13.0010 as a biotech immunological product per chapter note definitions. Excludes retail or dosed packings.
Infliximab Monoclonal Antibody
Infliximab (Remicade) is a chimeric monoclonal antibody neutralizing TNF-alpha for Crohn's disease and psoriasis. Classifies in HTS 3002.13.0010 for unmixed monoclonal immunological products from biotech, aligning with chapter's peptide/protein definition. Bulk for further processing.
Nivolumab Monoclonal Antibody
Nivolumab (Opdivo) human monoclonal antibody inhibits PD-1 for cancer immunotherapy applications. Bulk unmixed under HTS 3002.13.0010 as per immunological product notes for biotech proteins. Not in measured or retail forms.
Omalizumab Monoclonal Antibody
Omalizumab (Xolair) recombinant humanized monoclonal antibody binds IgE for severe asthma treatment. HTS 3002.13.0010 for unmixed monoclonal immunologicals from biotech processes. Bulk pharmaceutical grade.
Denosumab Monoclonal Antibody
Denosumab (Prolia) fully human monoclonal antibody inhibiting RANKL for osteoporosis. Classifies unmixed under HTS 3002.13.0010 per chapter immunological definitions. Bulk for formulation.
Ranibizumab Monoclonal Antibody
Ranibizumab (Lucentis) affinity-matured humanized monoclonal antibody fragment for wet AMD. HTS 3002.13.0010 bulk unmixed biotech product. Includes fragments per chapter notes.
Daratumumab Monoclonal Antibody
Daratumumab human IgG1k monoclonal antibody targeting CD38 for multiple myeloma. Unmixed HTS 3002.13.0010 immunological biotech product.
Atezolizumab Monoclonal Antibody
Atezolizumab humanized IgG1 blocking PD-L1 for bladder cancer. Bulk unmixed HTS 3002.13.0010.
Blinatumomab Monoclonal Antibody
Blinatumomab bispecific T-cell engager monoclonal for ALL. Unmixed biotech under HTS 3002.13.0010.
Adalimumab Monoclonal Antibody
Adalimumab (Humira) is a fully human monoclonal antibody against TNF-alpha, treating autoimmune diseases like rheumatoid arthritis. It is imported as unmixed bulk under HTS 3002.13.0010, meeting the definition of immunological products directly regulating immune processes via biotech-derived proteins. Not in retail forms or measured doses.
Bevacizumab Monoclonal Antibody
Bevacizumab (Avastin) is a humanized monoclonal antibody binding VEGF, used for colorectal and lung cancer treatments. HTS 3002.13.0010 covers this unmixed, biotech-produced immunological product not in retail packaging. It qualifies as a protein regulating immunological processes per chapter definitions.
Pembrolizumab Monoclonal Antibody
Pembrolizumab (Keytruda) is a humanized IgG4 monoclonal antibody blocking PD-1 for immunotherapy in melanoma and lung cancer. HTS 3002.13.0010 for unmixed biotech monoclonal antibodies regulating immunology. Supplied in bulk, non-retail.